CVS-Caremark Merger Creates Antitrust Complications

Law360, New York (November 2, 2006, 12:00 AM EST) -- With leading drug retailer CVS Corp. set to merge with leading pharmacy benefits manager Caremark Rx Inc., the Federal Trade Commission will likely take a long look at how the new company will affect competition in both the mail order and overall drug industries, according to a handful of U.S. law professors.

Most experts anticipate that the FTC will approve the deal, though CVS may be required to divest some of its assets.

The FTC will analyze whether the merger “stifles the dynamism of either market,”...
To view the full article, register now.